Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Statement re. Suspension

23 May 2016 11:34

RNS Number : 0178Z
Glenwick PLC
23 May 2016
 

23 May 2016

Glenwick Plc

("Glenwick" the "Company")

 

 

Statement re suspension of shares and potential acquisition

 

The Board of Glenwick (AIM: GWIK), notes the recent speculation regarding Glenwick and a potential acquisition.

Glenwick confirms that it is in advanced discussions for an acquisition. The potential acquisition would constitute a reverse takeover under the AIM Rules for Companies and would therefore, inter alia, be subject to shareholder approval.

As a result, the Company's ordinary shares have been suspended from trading on AIM as of 10.20am today. Trading in the Company's ordinary shares will be suspended until such time as an admission document containing a notice of general meeting of the Company is published in relation to the potential acquisition or the Company announces that the discussions have been terminated.

The Company will update shareholders as and when appropriate.

 

 For further information please contact:

 

 

FIM Capital Limited

 

Graham Smith

 

+44 1624 681 250

 

Allenby Capital Limited (Nominated Adviser and Joint-Broker)

John Depasquale

 

+44 203 328 5656

 

 

 

Peterhouse Corporate Finance Limited (Joint-Broker)

Lucy Williams / Heena Karani

 

+44 207 469 0933

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SRSBGGDUXXDBGLX

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.